EMAIL THIS PAGE TO A FRIEND

Clinical cancer research : an official journal of the American Association for Cancer Research

miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.


PMID 25724519

Abstract

Deregulation of miRNA has been implicated in the pathogenesis of multiple myeloma. We identified miR-137 and miR-197, mapped to the chromosome 1p (12)-(21) deletion region, and examined their antimyeloma activity as tumor suppressors. The expression of miR-137/197 was examined in multiple myeloma and normal plasma cells by qRT-PCR. Functional effect of miR-137/197 was analyzed by cell viability, apoptosis, clonogenic, and migration assays. Antimyeloma activity of miR-137/197 was further evaluated in vivo by lentiviral-based or lipid-based delivery in a mouse xenograft model of multiple myeloma. miR-137/197 expression was significantly lower in multiple myeloma cell lines and multiple myeloma patient samples compared with normal plasma cells. Transfection of miR-137/197 resulted in reduction of MCL-1 protein expression, as well as alteration of apoptosis-related genes, and induction of apoptosis, inhibition of viability, colony formation, and migration in multiple myeloma cells. MCL-1 was further validated as a direct target of miR-137/197. Conversely, overexpression of MCL-1 partially reverted the effect of miR-137/197. Importantly, in vivo lentiviral-mediated or intratumor delivery of miR-137/197 induced regression of tumors in murine xenograft models of multiple myeloma. Our study reveals a novel role of miR-137/197 as tumor suppressors in mediating apoptosis in multiple myeloma cells by targeting MCL-1. Our findings provide a proof-of-principle that lentivirus-based or formulated synthetic miR-137/197 exerts therapeutic activity in preclinical models, and support a framework for development of miR-137/197-based treatment strategies in patients with multiple myeloma.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300531
Anti-BCL2L11 (Ab-69) antibody produced in rabbit, affinity isolated antibody
PRS2065
Anti-Bim (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS3405
Anti-Bim (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
B7929
Anti-Bim antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA001473
Anti-CASP9 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4503332
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503333
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503334
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503335
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
C7729 Anti-Caspase 9 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4300683
Anti-Caspase 9 antibody produced in rabbit, affinity isolated antibody
SAB3500405
Anti-Caspase-9 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
WH0010018M1 Monoclonal Anti-BCL2L11 antibody produced in mouse, clone 2F10, purified immunoglobulin, buffered aqueous solution
WH0000842M1
Monoclonal Anti-CASP9 antibody produced in mouse, clone 3B8-4G2, purified immunoglobulin, buffered aqueous solution
SAB1403634
Monoclonal Anti-CASP9 antibody produced in mouse, clone 4F12-G6, purified immunoglobulin, buffered aqueous solution
C4356
Monoclonal Anti-Caspase 9 antibody produced in mouse, ~2 mg/mL, clone CAS9, purified immunoglobulin, buffered aqueous solution